NASDAQ:DAWN Day One Biopharmaceuticals Q3 2025 Earnings Report $7.51 +0.10 (+1.35%) Closing price 04:00 PM EasternExtended Trading$7.54 +0.03 (+0.40%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Day One Biopharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.28Beat/MissN/AOne Year Ago EPSN/ADay One Biopharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$38.20 millionBeat/MissN/AYoY Revenue GrowthN/ADay One Biopharmaceuticals Announcement DetailsQuarterQ3 2025Date10/29/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Day One Biopharmaceuticals Earnings HeadlinesDay One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025October 21 at 8:30 AM | globenewswire.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of "Buy" by AnalystsOctober 19 at 2:23 AM | americanbankingnews.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.October 21 at 2:00 AM | Brownstone Research (Ad)Day One Biopharmaceuticals Reprices Stock Options for RetentionOctober 10, 2025 | msn.comPiper Sandler Starts Coverage on Day One (DAWN) with Overweight RatingSeptember 8, 2025 | insidermonkey.comDay One Biopharmaceuticals initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comSee More Day One Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email. Email Address About Day One BiopharmaceuticalsDay One Biopharmaceuticals (NASDAQ:DAWN) (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit. The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes. Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.View Day One Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings CME Group (10/22/2025)Lam Research (10/22/2025)O'Reilly Automotive (10/22/2025)Tesla (10/22/2025)Amphenol (10/22/2025)Barclays (10/22/2025)Boston Scientific (10/22/2025)GE Vernova (10/22/2025)Hilton Worldwide (10/22/2025)International Business Machines (10/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
